Alembic
Touching Lives over 100 years

Date: 24th January, 2020

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd.
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals receives USFDA Final Approval for Bosentan Tablets, 62.5 mg and 125 mg.**

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Bosentan Tablets, 62.5 mg and 125 mg.

Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
**For Alembic Pharmaceuticals Limited**

**Charandeep Singh Saluja**
**Company Secretary**

Encl.: A/a.

Alembic
Touching Lives over 100 years

**PRESS RELEASE**

24th January, 2020, Vadodara, India

**Alembic Pharmaceuticals announces USFDA Final Approval for Bosentan Tablets, 62.5 mg and 125 mg.**

Alembic Pharmaceuticals Limited (Alembic) today announced it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosentan Tablets, 62.5 mg and 125 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tracleer Tablets, 62.5 mg and 125 mg, of Actelion Pharmaceuticals Limited. Bosentan Tablets indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1).

Bosentan Tablets, 62.5 mg and 125 mg have an estimated market size of US$ 68 million for twelve months ending September 2019 according to IQVIA.

Alembic has a cumulative total of 114 ANDA approvals (102 final approvals and 12 tentative approvals) from USFDA.

**About Alembic Pharmaceuticals Limited**

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about Alembic can be found at http://www.alembicpharmaceuticals.com/; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:


| | |
|---|---|
| Ajay Kumar Desai<br><br>Phone: +91 22 - 306 11681<br><br>Email: ajay.desai@alembic.co.in | Mitanshu Shah<br><br>Phone: +91 265 - 3007630<br><br>Email: mitanshu.shah@alembic.co.in |


ALEMBIC PHARMACEUTICALS LIMITED VADODARA 390 003